Company: CI
Filing Date: 2025-03-19
Form Type: 8-K
Source: 0001140361-25-009365
Chunk: 1

Company: Cigna Group
Filing Date: 2025-03-19
Form: 8-K
Item: Item 9.01
Chunk 1
---
Item 9.01      Financial Statements and Exhibits.  

(d) Exhibits

  Exhibit      Description of Exhibit                                               
      No.                                                                           
     99.1      Press Release, issued March 19, 2025.                                
 ────────────────────────────────────────────────────────────────────────────────────
      104      Cover Page Interactive Data File (embedded within the Inline XBRL).  

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Current Report on Form 8-K (the “ Report”), and oral statements made with respect to information contained in this Report, may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial
condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or
expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those
expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing
industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition and other pressures that could compress our margins or result in premiums
that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health
care payors, physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes
in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our